Gland Pharma · NSE: GLAND · BSE: 543245
Q1 FY22 results · Apr–Jun 2021
Gland Pharma reported revenue from operations of ₹1,153.90 crore and net profit of ₹350.65 crore for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,153.90 | — | — | 887.75 | +30.0% |
| Other income | 61.84 | — | — | 47.21 | +31.0% |
| Total income | 1,215.74 | — | — | 934.96 | +30.0% |
| Profit before tax | 471.84 | — | — | 348.94 | +35.2% |
| Net profit for the period | 350.65 | — | — | 260.41 | +34.7% |
| EPS, basic (₹) | 21.41 | — | — | 15.93 | +34.4% |
| Net margin (%) | 30.4 | — | 29.3 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,153.90 | — | — | 887.75 | +30.0% |
| Other income | 61.84 | — | — | 47.21 | +31.0% |
| Total income | 1,215.74 | — | — | 934.96 | +30.0% |
| Profit before tax | 471.86 | — | — | 348.99 | +35.2% |
| Net profit for the period | 350.68 | — | — | 260.45 | +34.6% |
| EPS, basic (₹) | 21.41 | — | — | 15.93 | +34.4% |
| Net margin (%) | 30.4 | — | 29.3 |
Consolidated
- Filed with BSE
- 22 Jul 2021, 13:02 IST
- Board meeting
- 21 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Jul 2021, 13:02 IST
- Board meeting
- 21 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE